Clinical Trials Logo

Type 2 Diabetes Mellitus clinical trials

View clinical trials related to Type 2 Diabetes Mellitus.

Filter by:

NCT ID: NCT06258148 Not yet recruiting - Clinical trials for Type 2 Diabetes Mellitus

Phase 3 Study of TG103 Injection Monotherapy in Treatment of Type 2 Diabetes Mellitus

Start date: March 2024
Phase: Phase 3
Study type: Interventional

This is a randomized, double-blind, placebo-parallel, multicenter phase 3 clinical trial to evaluate the efficacy of TG103 injection 7.5mg and 15mg once a week monotherapy compared with placebo in subjects with type 2 diabetes with poor glycemic control after diet and exercise.

NCT ID: NCT06256419 Recruiting - Clinical trials for Type 2 Diabetes Mellitus

Association of Gene Polymorphism With Susceptibility to T2DM and the Therapeutic Responses to Exenatide in Chinese Patients With T2DM

Start date: January 1, 2024
Phase: N/A
Study type: Interventional

This is a retrospective cohort study of patients with T2DM who were treated with exenatide twice daily as a part of their diabetes care for at least 12 months. The objective of this study is to investigate the influence of T2DM susceptibility gene polymorphisms (NOS1AP, KCNQ1, TCF7L2, WSF1, GLP-1R, etc.) on the efficacy of GLP-1 RA (exenatide, liraglutide, etc.), to identify the variables that can predict the efficacy of GLP-1 RA, and to evaluate the weight of these variables on the efficacy.

NCT ID: NCT06254014 Not yet recruiting - Clinical trials for Type 2 Diabetes Mellitus

A Phase 3 Study to Evaluate the Efficacy of JY09 Compared With Placebo in T2DM Patients

Start date: March 1, 2024
Phase: Phase 3
Study type: Interventional

The main purpose of this study is to investigate the efficacy and safety of JY09 versus placebo in patients with type 2 diabetes mellitus (T2DM) inadequately controlled by diet and exercise alone

NCT ID: NCT06235762 Completed - Hypertension Clinical Trials

The Effects of Nutritional Intervention on Health Parameters in Participants With Type 2 Diabetes Mellitus

Start date: August 16, 2020
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to evaluate the effects of nutritional intervention on anthropometric, biochemical and cardiovascular parameters in participants with type 2 diabetes mellitus. Participants will be distributed into 2 groups (control and intervention). Participants in the control group will only undergo conventional medical assessment and participants in the intervention group will receive the same medical care, concomitantly with nutritional assessment. The nutritional intervention is expected to reduce anthropometric data, glycemic and cardiovascular parameters in participants with T2DM, as opposed to the control group.

NCT ID: NCT06235086 Not yet recruiting - Clinical trials for Type 2 Diabetes Mellitus

Phase 3 Study of TG103 Injection Combined With Metformin in Treatment of Type 2 Diabetes Mellitus

Start date: March 2024
Phase: Phase 3
Study type: Interventional

This is a randomized, open-label, dulaglutide-controlled, multicenter Phase 3 trial to evaluate the efficacy, safety, and immunogenicity of different doses of TG103 injection in combination with metformin in subjects with type 2 diabetes with poor glycemic control treated with metformin monotherapy.

NCT ID: NCT06226727 Recruiting - Clinical trials for Type 2 Diabetes Mellitus

A Study to Evaluate the Pharmacokinetics and the Safety After Administration of "BR1019" and Co-administration of "BR1019-1" and "BR1019-2"

Start date: February 14, 2024
Phase: Phase 1
Study type: Interventional

The objective of this clinical study is to evaluate the pharmacokinetics and the safety after administration of "BR1019" and co-administration of "BR1019-1" and "BR1019-2" in healthy volunteers

NCT ID: NCT06220773 Not yet recruiting - Clinical trials for Type 2 Diabetes Mellitus

A Study to Evaluate the Efficacy and Safety of BR1019A and BR1019B Combination Therapy

Start date: March 2024
Phase: Phase 3
Study type: Interventional

The objective of this clinical study is to Evaluate the Efficacy and Safety of BR1019A and BR1019B combination therapy in Patients with Essential Hypertension and Type 2 Diabetes Mellitus

NCT ID: NCT06219590 Recruiting - Clinical trials for Type 2 Diabetes Mellitus

Acetylcholine Iontophoresis As A New Challenge With Type 2 Diabetic Peripheral Neuropathy: A Possible New Therapy

Start date: October 28, 2023
Phase: N/A
Study type: Interventional

The investigators initial study opened the way for randomized trials that monitor the effects of acetylcholine (Ach) iontophoresis vasodilators on endothelial nitric oxide synthetase (NOS) to develop a transdermal treatment that is effective, free from systemic adverse effects.

NCT ID: NCT06217887 Recruiting - Clinical trials for Type 2 Diabetes Mellitus

Efficacy Comparison of Polyethylene Glycol Loxenatide and Gliclazide on the Brain Function in T2DM Patients

Start date: May 10, 2020
Phase: N/A
Study type: Interventional

This is a prospective, randomized, open label, parallel,4-month study to explore and evaluate the therapeutic effects of polyethylene glycol loxenatide on the cognitive function, olfactory function, and odor-induced brain activation in T2DM patients with normal cognitive status or MCI.

NCT ID: NCT06212778 Recruiting - Clinical trials for Type 2 Diabetes Mellitus

Relationship Between Nutritional Status, Hand Grip Strength, and Fatigue in Hospitalized Older Adults With Type 2 Diabetes Mellitus.

Start date: September 26, 2023
Phase:
Study type: Observational

As the proportion of the elderly population increases, so does the number of people suffering from diabetes mellitus (DM). Fatigue is common in elderly patients with type 2 diabetes, and malnutrition may lead to a decrease in muscle strength, thereby aggravating their fatigue symptoms; however, there is still a lack of relevant research on this group in Taiwan. Therefore, the purposes of this study are to understand the current status and correlation of basic attributes, nutritional status, handgrip strength and fatigue in hospitalized older adults with type 2 diabetes mellitus.